In April 2026, the FDA approved orforglipron, the first oral small-molecule, non-peptide GLP-1 receptor agonist for weight management
Vladimir cabin developed thyimolin, an injectable and oral treatment that showed positive immune markers, such as improved CD4 and CD8 cells, and a more youthful immune state 10s
This month, the 2026 San Diego Business Impact Awards recognized local businesses making an impact in clean energy, biotech, hospitality, and beyond Renewable energy companies building hundreds of power plants
In this model mobilferrin could serve as a rheostat sensitive to plasma iron concentrations
"Best" implies a safe option exists among them it doesn't
Is glutathione helpful for muscle recovery